ANI Pharma has outlined key pillars of its strategy to drive growth in the coming quarters as the company reported a slight increase in revenues in the fourth quarter of 2021. The company’s recent purified Cortrophin Gel launch is off to a good start, as ANI leadership counts on its commercial longevity.
ANI Pharmaceuticals, Inc.has expressed confidence in its “strong foundation in place to drive sustainable growth” – despite facing increased competitive intensity and resulting pricing pressures in both its established brands and generics business – based on the key pillars of the company’s growth strategy.
The company has reported revenues of $60.9m for the fourth quarter of 2021, up by 6% compared to the $57.3m reported in the prior year period
Viatris continues to make progress on remediation at the firm’s stricken manufacturing facility in Indore, India, following a warning letter and import alert delivered at the tail end of 2024.
Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.
Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.
Reflecting conversations across the wider pharmaceutical industry, Pfizer’s earnings call for the first quarter of 2025 focused on the sector’s response to the potential imposition of tariffs by the Trump administration.
Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.
Reflecting conversations across the wider pharmaceutical industry, Pfizer’s earnings call for the first quarter of 2025 focused on the sector’s response to the potential imposition of tariffs by the Trump administration.
Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.
